Lysosomal membrane leaks and doxorubicin heart damage in cancer treatment
Official title: Redefining the Role of lysosomal membrane permeabilization (LMP) inDoxorubicin-induced Cardiotoxicity
Funded at New York Inst of Technology · NIH-11360249 · Data updated 2026-11-12
This grant looks at how a heart cell’s lysosomes react to the chemotherapy drug doxorubicin and how this may cause heart damage in cancer patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Inst of Technology NIH-funded |
| Lab location | 1 site (Old Westbury, United States) |
| Project start | July 15, 2026 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $573,750 |
| NIH project number | 1R15HL179642-01A1 |
| Project ID | NIH-11360249 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients who receive doxorubicin for cancer treatment could benefit from improved heart protections and safer dosing in the future.
✕Less likely to help
People not receiving doxorubicin or without cardiac risk factors may see limited direct benefit.
What this research studies
Doxorubicin is a common cancer drug that can harm the heart. This project focuses on lysosomal membrane permeabilization in heart muscle cells and how it affects cell survival during doxorubicin exposure. Researchers will study how changes inside lysosomes influence heart cell health, with a special look at the enzyme cathepsin D and its activity. The goal is to understand pathways that lead to cardiotoxicity so future therapies can protect the heart during cancer treatment.
Why it matters
Potential benefit: If successful, the work could lead to strategies that prevent or reduce doxorubicin-related heart damage for cancer patients.
How similar studies have gone: Previous work has linked lysosomal dysfunction to cardiotoxicity, but this project aims to clarify the specific role of lysosomal lumen environment and CTSD activity.
Where this research is happening
-
New York Inst of Technology
Old Westbury, United States Active
Researchers
- Principal investigator: Kobayashi, Satoru — New York Inst of Technology
- Study coordinator: Kobayashi, Satoru
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
High-throughput 3D human heart tissue to screen drug safety
A Johns Hopkins team is creating a high-throughput, 3D human heart tissue model to test drug safety on human heart cells.
-
Precision imaging of heart damage from cancer treatment using metabolic MRI biomarkers
Researchers will use advanced MRI to find early metabolic signs of heart injury in cancer patients treated with common drugs, so doctors can protect the heart earlier.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.